Anti-Plasma Kallikrein 1B (Fletcher factor, Plasma Kallikrein, PK), Carboxy end catalytic domain

Applied Biological Materials

Anti-Plasma Kallikrein 1B (Fletcher factor, Plasma Kallikrein, PK), Carboxy end catalytic domain

9

This antibody is specific for Plasma Kallikrein 1B (carboxy end of catalytic domain)

Western Blot

Research Use Only

Polyclonal

1 ug/ul

Rabbit

IgG

The antibody is a rabbit polyclonal antibody made to the serine protease plasma kallikrein. The antibody is made to a synthetic peptide based on the carboxy end of the catalytic domain of human plasma kallikrein. The antibody reacts with human, mouse and rat plasma Kallikrein. The antibody has been peptide-affinity purified, concentrated to 1.0 mg/ml, with the addition of 0.05% sodium azide as preservative and 50% glycerol as cryoprotectant. Plasma Kallikrein 1B, also known as Fletcher factor, is a serine proteinase of the S1 family, and is secreted by the liver, kidney, adrenal gland and placenta. The zymogen is referred to as prekallikrein (PK) and is activated by Factor XIIa to an active two-chain form, plasma kallikrein. In Fletcher syndrome plasma kallikrein is deficient, resulting in a prolonged partial thromboplastin time (PT). Plasma Kallikrein cleaves at P1 Arg and Lys, and is responsible for liberating bradykinin from kininogen. Factor XIIa cleavage at Arg371-Ile372 generates two chains, a heavy and light chain, which resolve on reduced SDS PAGE gels, but remain associated in solution. Normal plasma kallikrein concentrations range from 35-50 ug/ml. Plasma kallikrein is produced as a 638 amino acid protein with predicted mass of 71,370 Dalton and a pI of 9.30. The 19 amino acid signal sequence is followed by four Apple cystein-rich domains in the heavy chain. The catalytic domain is in the light chain, and contains the canonical His-Asp-Ser catalytic triad. Glycosylation and other post translational modifications give plasma kallikrein a higher apparent molecular weights of 88 and 85 kDa . An autocatalytic cleavage of plasma kallikrein at Lys140-Ala141 generates a form termed ? -Kallikrein, with reduced enzymatic activity. RP3-Plasma Kallikrein 1B recognizes the zymogen form of plasma kallikrein (PK) and the light chain of factor XIIa cleaved plasma Kallikrein. Plasma Kallikrein is largely complexed with its substrate, H-kininogen in plasma, and plasma Kallikrein released from H-kininogen can cleave Factor XII, prorenin, prourokinase, C-1 complement, as well as converting factor XIIa to a more active form, factor XIIf. Plasma Kallikrein is partially inhibited by ? -2 Macroglobulin and completely inhibited by C-1 inhibitor in-vivo. Recommended starting concentration for Western blots is 1:1,000 when using colorimetric substrates such as BCIP/NBT, and 1:5,000 for chemiluminescent substrates. Higher concentrations of antibody may be needed for samples from more distantly related species. EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen. FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Other Species

-20°C,2°C to 8°C

12352203